Vertex Receives US FDA Approval for ALYFTREK: A Breakthrough CFTR Modulator for Cystic Fibrosis
Vertex Pharmaceuticals Incorporated announced that the FDA had approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily triple combination CFTR modulator for the treatment of cystic fibrosis. ALYFTREK is approved for people aged 6 years and older with at least one F508del mutation or another responsive CFTR mutation. This marks Vertex’s fifth CFTR modulator to receive FDA approval, advancing its mission to improve the lives of those living with CF.
“ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone ...
